Cure Today

Cabometyx Demonstrates PFS Benefit Versus Placebo in GI-NETs

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced gastrointestinal NETs. The phase 3 CABINET trial demonstrated that Cabometyx ...

Exelixis CABINET Win Extends CABOMETYX Reach And Raises Valuation Questions

Exelixis (NasdaqGS:EXEL) reported pivotal phase 3 CABINET trial results for CABOMETYX in advanced neuroendocrine tumors at ASCO 2026. The trial showed a significant improvement in progression free ...
Yahoo Finance

How Investors Are Reacting To Exelixis (EXEL) Expanding Beyond CABOMETYX With New Colorectal Cancer Trials

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Cure Today

Cabometyx Failed to Improve Survival in Advanced Bladder Cancer

While Cabometyx had a favorable side effect profile, it did not lead to a significant survival advantage over placebo in a clinical trial. Post-chemotherapy Cabometyx (cabozantinib) is a tolerable ...
pharmaphorum

NICE rejects Ipsen’s Cabometyx in thyroid cancer

Ipsen’s Cabometyx should not be used by the NHS for patients with differentiated thyroid cancer who have either not responded to or are ineligible for radioactive iodine therapy, according to draft ...
Morningstar

Ipsen Earnings: Robust Sales Growth Driven by Dysport and Cabometyx; Shares Moderately Undervalued

Ipsen IPN reported strong first-quarter results highlighted by total revenue of nearly $741 million, representing about 8% growth from the prior-year period. Strong revenue contributions from Dysport ...
Business Wire

Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results demonstrating efficacy benefits regardless of prior nephrectomy status with CABOMETYX ® (cabozantinib) in ...
Nasdaq

Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer

PARIS--(BUSINESS WIRE)-- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® ...
Benzinga.com

FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors

The U.S. Food and Drug Administration has approved Exelixis Inc.’s (NASDAQ:EXEL) Cabometyx (cabozantinib) for two indications in adult and pediatric patients with previously treated, unresectable, ...
Morningstar

Ipsen Earnings: Strong Dysport, Cabometyx Sales Drive Top-Line Growth, Shares Slightly Undervalued

Ipsen IPN reported strong second-quarter results highlighted by total revenue of EUR 795 million, representing nearly 7% growth from the prior-year period. Strong revenue contributions from Dysport ...
Nasdaq

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in ...

PARIS--(BUSINESS WIRE)-- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® ...